177 related articles for article (PubMed ID: 30940294)
1. VASH2 Promotes Cell Proliferation and Resistance to Doxorubicin in Non-Small Cell Lung Cancer via AKT Signaling.
Tan X; Liao Z; Zou S; Ma L; Wang A
Oncol Res; 2020 Feb; 28(1):3-11. PubMed ID: 30940294
[TBL] [Abstract][Full Text] [Related]
2. Vasohibin2 promotes adriamycin resistance of breast cancer cells through regulating ABCG2 via AKT signaling pathway.
Ma D; Wu L; Li S; Sun Z; Wang K
Mol Med Rep; 2017 Dec; 16(6):9729-9734. PubMed ID: 29039601
[TBL] [Abstract][Full Text] [Related]
3. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
Cao Z; Liang N; Yang H; Li S
Cell Prolif; 2017 Oct; 50(5):. PubMed ID: 28762597
[TBL] [Abstract][Full Text] [Related]
4. Cell adhesion molecule 4 suppresses cell growth and metastasis by inhibiting the Akt signaling pathway in non-small cell lung cancer.
Luo F; Zhao Y; Liu J
Int J Biochem Cell Biol; 2020 Jun; 123():105750. PubMed ID: 32325280
[TBL] [Abstract][Full Text] [Related]
5. MiR-4299 suppresses non-small cell lung cancer cell proliferation, migration and invasion through modulating PTEN/AKT/PI3K pathway.
Yang WB; Zhang WP; Shi JL; Wang JW
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3408-3414. PubMed ID: 29917192
[TBL] [Abstract][Full Text] [Related]
6. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
7. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-specific protease 44 inhibits cell growth by suppressing AKT signaling in non-small cell lung cancer.
Zhang YK; Tian WZ; Zhang RS; Zhang YJ; Ma HT
Kaohsiung J Med Sci; 2019 Sep; 35(9):535-541. PubMed ID: 31197957
[TBL] [Abstract][Full Text] [Related]
10. The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling.
Wu DM; Zhang T; Liu YB; Deng SH; Han R; Liu T; Li J; Xu Y
Cell Death Dis; 2019 Apr; 10(5):349. PubMed ID: 31024010
[TBL] [Abstract][Full Text] [Related]
11. Musashi1 Promotes Non-Small Cell Lung Carcinoma Malignancy and Chemoresistance via Activating the Akt Signaling Pathway.
Lang Y; Kong X; He C; Wang F; Liu B; Zhang S; Ning J; Zhu K; Xu S
Cell Physiol Biochem; 2017; 44(2):455-466. PubMed ID: 29141252
[TBL] [Abstract][Full Text] [Related]
12. B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3.
Fan X; Wang Y; Jiang T; Cai W; Jin Y; Niu Y; Zhu H; Bu Y
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772705
[TBL] [Abstract][Full Text] [Related]
13. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
Zhou Y; Li S; Li J; Wang D; Li Q
Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
[TBL] [Abstract][Full Text] [Related]
14. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells.
Ko JC; Syu JJ; Chen JC; Wang TJ; Chang PY; Chen CY; Jian YT; Jian YJ; Lin YW
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):383-91. PubMed ID: 26046675
[TBL] [Abstract][Full Text] [Related]
16. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912
[TBL] [Abstract][Full Text] [Related]
17. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
18. MZT2A promotes NSCLC viability and invasion by increasing Akt phosphorylation via the MOZART2 domain.
Wang H; Jiang X; Cheng Y; Ren H; Hu Y; Zhang Y; Su H; Zou Z; Wang Q; Liu Z; Zhang J; Qiu X
Cancer Sci; 2021 Jun; 112(6):2210-2222. PubMed ID: 33754417
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of CASS4 promotes invasion in non-small cell lung cancer by activating the AKT signaling pathway and inhibiting E-cadherin expression.
Li A; Zhang W; Xia H; Miao Y; Zhou H; Zhang X; Dong Q; Li Q; Qiu X; Wang E
Tumour Biol; 2016 Nov; 37(11):15157-15164. PubMed ID: 27677288
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
